These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 889713)

  • 1. Haemophilia Centre Director's annual statistics for 1975.
    Biggs R; Spooner RJ
    Br J Haematol; 1977 Jul; 36(3):447-9. PubMed ID: 889713
    [No Abstract]   [Full Text] [Related]  

  • 2. Haemophilia treatment in the United Kingdom from 1969 to 1974.
    Biggs R
    Br J Haematol; 1977 Apr; 35(4):487-504. PubMed ID: 871406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired haemophilia A treated with recombinant porcine factor VIII: a single centre UK experience.
    Khan D; Raza-Burton S; Baker P; Harper S; Beavis J; Desborough M; Shapiro S
    Br J Haematol; 2020 May; 189(4):e130-e133. PubMed ID: 32141061
    [No Abstract]   [Full Text] [Related]  

  • 5. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization.
    Colvin BT; Hay CR; Hill FG; Preston FE
    Br J Haematol; 1995 Apr; 89(4):908-10. PubMed ID: 7772532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to review the way we estimate access to haemophilia concentrates worldwide.
    Farrugia A
    Haemophilia; 2017 May; 23(3):e235-e237. PubMed ID: 28520206
    [No Abstract]   [Full Text] [Related]  

  • 7. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
    Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
    Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia treatment. Side effects during immune tolerance induction.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Haematologica; 2000 Oct; 85(10 Suppl):75-7. PubMed ID: 11187878
    [No Abstract]   [Full Text] [Related]  

  • 10. First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.
    Collins P; Chalmers E; Alamelu J; Hay C; Liesner R; Makris M; Mathias M; Payne J; Rangarajan S; Richards M; Talks K; Tunstall O; Williams M; Hart DP
    Haemophilia; 2017 Sep; 23(5):654-659. PubMed ID: 28574205
    [No Abstract]   [Full Text] [Related]  

  • 11. Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom.
    Biggs R
    Br J Haematol; 1974 Mar; 26(3):313-29. PubMed ID: 4852608
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: Supply of blood-clotting-factor VIII for treatment of haemophilia.
    Biggs R
    Lancet; 1974 Jun; 1(7870):1339. PubMed ID: 4134308
    [No Abstract]   [Full Text] [Related]  

  • 13. Prophylaxis in children with haemophilia - the Polish experience.
    Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
    Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
    [No Abstract]   [Full Text] [Related]  

  • 14. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
    Lowe GD
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of factor VIII replacement during open heart surgery in a patient with haemophilia A.
    Stine KC; Becton DL
    Haemophilia; 2006 Jul; 12(4):435-6. PubMed ID: 16834747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hepatitis A in patients with haemophilia A.
    Peerlinck K; Vermylen J
    Lancet; 1993 Jan; 341(8838):179. PubMed ID: 8093776
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV infection. UK haemophiliacs win compensation.
    Aldhous P
    Nature; 1990 Dec 20-27; 348(6303):667. PubMed ID: 2124331
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of haemophilia in the elderly.
    Miesbach W; Krekeler S; Alesci S
    Hamostaseologie; 2009 Oct; 29 Suppl 1():S29-31. PubMed ID: 19763355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic model for factor VIII dosing during active haemorrhage in patients with haemophilia A.
    Ho AM; Dion P; Karmakar MK; Cheng G; Derrick JL; Chung DC; Tay BA
    Anaesthesia; 2001 Aug; 56(8):785-90. PubMed ID: 11493246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confidential documents in HIV/haemophilia litigation.
    Brahams D
    Lancet; 1990 Sep; 336(8718):805. PubMed ID: 1976159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.